AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-23 (Cancelled).

- 24. (Cancel).
- 25. (Currently Amended) A <u>The</u> conjugate as claimed in claim 24 <u>29</u> wherein the bioreductive moiety is non-cytotoxic.

26-28 (Cancel).

29. (Currently Amended) A conjugate as claimed in claim 28 which A bioreductive conjugate comprising a bioreductive moiety with at least one therapeutic agent linked thereto and physiologically acceptable derivatives thereof wherein the bioreductive moiety incorporates an aromatic ring substituted with a nitro group and the conjugate is such that bioreduction of the nitro group causes release of the therapeutic agent by a through bond elimination and the residue of the bioreductive moiety to undergo an intramolecular cyclization reaction in which the nitrogen of the original nitro group provides an atom of the thus formed ring,

wherein the therapeutic agent to be released on bioreduction is bonded to the aromatic ring via a side chain incorporating one or more double bonds which are located in the side chain between said therapeutic agent and the aromatic ring, which is/are conjugated to the aromatic ring, and which is/are displaceable to provide for elimination of said therapeutic agent moiety and formation of an arrangement of double bonds such that the residue of the bioreductive moiety is capable of undergoing the intramolecular cyclisation reaction, and

wherein said conjugate is of the general formula (I)

$$R_1$$
 R_2
 R_1
 R_3
 R_4
 R_4
 R_4
 R_4

in which

the dashed lines represent completion of a substituted or unsubstituted aromatic ring system;

Drug is a therapeutic agent;

X is a linker (which may be part of the drug) and <u>is</u> may for example be O, -NH, S, an amide, alcohol, phenol, carboxylic acid (carboxylate), carbonate, phosphate, sulphate or sulphonate;

 R_1 , R_2 , and R_3 and R_4 are independently hydrogen, and R_4 is a substituted or unsubstituted alkyl, aryl, halide, amine, alkoxy, ether, ester, alcohol, phenol, nitro, amide, thiol, sulphate, phosphate, or phosphonate; and

n is 1 to 3.

30. (Currently Amended) A <u>The</u> conjugate as claimed in claim 29 which wherein said conjugate is of the general formula (II)

(II)
$$Z_{2}$$

$$Z_{3}$$

$$Z_{4}$$

$$R_{1}$$

$$R_{3}$$

$$R_{4}$$
Drug

wherein Z, Z_2 , Z_3 and Z_4 are independently hydrogen, substituted or unsubstituted alkyl, aryl, halide, amine, alkoxy, ether, ester, alcohol, phenol, nitro, amide, thiol, sulphate, phosphate, or phosphonate.

31. (Currently Amended) A <u>The</u> conjugate as claimed in claim 29 which wherein said conjugate is of the general formula (III)

FREEMAN et al Appl. No. 09/763,236 March 23, 2004

(III)
$$Z_1$$
 NO_2 R_2 X $Drug$

32. (Currently Amended) A <u>The</u> conjugate as claimed in claim 29 wherein n=1.

33-36 (Cancel).

- 37. (Currently Amended) A <u>The</u> conjugate as claimed in claim 24 <u>29</u> wherein the therapeutic agent is an anti-infective, analgesic, anaesthetic, anti-inflammatory or anti-neoplastic agent.
- 38. (Currently Amended) A therapeutic composition comprising a bioreductive the conjugate as claimed in claim 24 29 in conjunction with a therapeutically acceptable carrier.

39. (Cancelled).

40-45 (Cancel)

- 46. (Currently Amended) The conjugate according to claim 29 wherein R₁, R₂, R₃-and R₄ is a are independently hydrogen, substituted or unsubstituted C₁₋₄alkyl, aryl, halide, amine, alkoxy, ether, ester, alcohol, phenol, nitro, amide, thiol, sulphate, phosphate, or phosphonate.
- 47. (Previously Presented) The conjugate according to claim 30 wherein Z_1 , Z_2 , Z_3 and Z_4 are independently hydrogen, substituted or unsubstituted C_{1-4} alkyl, aryl, halide, amine, alkoxy, ether, ester, alcohol, phenol, nitro, amide, thiol, sulphate, phosphate, or phosphonate.
- 48. (Previously Presented) The conjugate according to claim 37 wherein the anti-infective agent is an antiobiotic or antiviral agent.
- 49. (Currently Amended) A method of therapeutic treatment, wherein the therapeutic treatment is for The method according to claim 42 wherein said other arthritic

FREEMAN et al Appl. No. 09/763,236 March 23, 2004

eondition is osteoarthritis, comprising administering to a subject in need thereof a therapeutically effective amount of the bioreductive conjugate as claimed in claim 29.

50. (Cancel).